Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07734519) titled 'Pelashield vs Xeroform' on July 24.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor).
Primary Sponsor: Wake Forest University Health Sciences
Condition:
Skin Graft
Intervention:
Device: Pelashield
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: August 2026
Target Sample Size: 40
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07734519
Disclaimer: Curated by HT Syndication....